Cardiomagnil, 150 mg+30.39 mg 100 pcs

Indications

– Unstable angina and stable angina;

– Prevention of recurrent myocardial infarction;

– Prevention of recurrent transient ischemic attack (TIA) and recurrent ischemic stroke in patients who have previously suffered a stroke;

– Prevention of thrombotic complications after surgeries and invasive vascular interventions (such as coronary artery bypass surgery, carotid endarterectomy, arteriovenous bypass, angioplasty and stenting of coronary arteries, angioplasty of carotid arteries).

Active ingredient

Composition

One tablet contains

The active ingredients:

Acetylsalicylic acid ……………………………………………75 mg / 150 mg

Magnesium hydroxide ……………………………………………………….15.2 mg / 30.39 mg

Excipients: corn starch, microcrystalline cellulose, magnesium stearate, potato starch; coating: hypromellose (methylhydroxypropylcellulose 15), propylene glycol, talc.

How to take, the dosage

Interaction

Simultaneous use of Cardiomagnil with methotrexate may increase hematological toxicity of methotrexate due to decreased renal clearance and its displacement from plasma proteins binding. Use with methotrexate in a dose greater than 15 mg per week is contraindicated. Administration with methotrexate in dose less than 15 mg per week is possible with special caution in case if the benefit to the patient exceeds the risk.

Concomitant use of the drug with other NSAIDs containing salicylates in high doses shows an increased risk of ulcerogenic effects and gastrointestinal bleeding.

When used concomitantly, ASK increases the effect of the following drugs:

– methotrexate by reducing renal clearance and displacing it from binding to proteins

– heparin and indirect anticoagulants by impairing platelet function and displacing indirect anticoagulants from binding to proteins

/p>

– thrombolytic and anti-aggregant and anticoagulant drugs

– digoxin due to decrease of its renal excretion

– Hypoglycemic oral agents (sulfonylurea derivatives) and insulin due to the hypoglycemic properties of ASA at high doses and displacing sulfonylurea derivatives from plasma proteins

– Valproic acid due to its displacement from protein binding

When used concomitantly (for one day) with metamizole and some NSAIDs (including ibuprofen and naproxen) antagonism is noted with respect to irreversible inhibition of platelet function due to the action of ASA.

The clinical significance of this effect is unknown. Combination of ASA with metamizole or NSAIDs (including ibuprofen or naproxen) in patients at high risk of cardiovascular disease is not recommended because of possible reduction of cardioprotective effects of ASA.

When taking ASA in combination with ethanol (alcohol) an increased risk of gastrointestinal mucosal damage and prolongation of bleeding time due to mutual enhancement of ASA and ethanol effects is noted.

Asc attenuates the effects of uricosuric agents (benzbromaron) due to competitive tubular elimination of uric acid.

Asc increases the elimination of salicylates, systemic glucocorticosteroids (GCS) weaken their effects.

The antacids and colestiramine reduce absorption of the drug.

The concomitant use of ASA with selective serotonin reuptake inhibitors may increase the risk of upper gastrointestinal bleeding due to possible synergistic effects.

When concomitant use of diuretics with ASA in high doses, a decrease in glomerular filtration rate due to decreased renal prostaglandin synthesis has been noted.

When angiotensin-converting enzyme inhibitors (ACE) are combined with high doses of ASA, a decrease in glomerular filtration rate as a result of inhibition of prostaglandins that have a vasodilator effect is noted. In addition, a weakening of antihypertensive effect of ACE inhibitors has been noted.

If you are taking the drugs listed above or other drugs (including over-the-counter medications), talk to your doctor before taking this medicine.

Special Instructions

Synopsis

Contraindications

Hypersensitivity to ASA, excipients of the drug and other NSAIDs, cerebral hemorrhage; susceptibility to bleeding (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis); bronchial asthma, induced by taking salicylates and NSAIDs; complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and sinuses and intolerance to acetylsalicylic acid or other NSAIDs, including COX-2 inhibitors (including a history); gastrointestinal erosive-ulcerative lesions (acute phase); gastrointestinal bleeding; severe hepatic impairment; severe renal failure (creatinine clearance less than 30 ml/min); chronic heart failure III-IV functional class according to NYHA classification; Pregnancy (I trimester, II trimester more than 20 weeks, and III trimester of pregnancy); breastfeeding period; glucose-6-phosphate dehydrogenase deficiency; concomitant use with methotrexate (more than 15 mg per week); children under 18 years of age.

With caution

. In gout, hyperuricemia, history of gastrointestinal ulcers or gastrointestinal bleeding, impaired liver function, impaired renal function, bronchial asthma, hay fever, nasal polyposis, hypersensitivity to analgesics, anti-inflammatory drugs, anti-rheumatic drugs, and allergic reactions to other substances, in anticipated surgical procedures (including minor, such as tooth extraction) In the second trimester of pregnancy up to 20 weeks.

Caution should be exercised with concomitant therapy with the following drugs:

Methotrexate at a dose of less than 15 mg per week; anticoagulant, thrombolytic, or other antiaggregant agents; methamisole and NSAIDs (including ibuprofen, naproxen), digoxin, oral hypoglycemic drugs (sulfonylurea derivatives) and insulin, valproic acid, ethanol, selective serotonin reuptake inhibitors).

If you have any of the above conditions, you should consult your doctor before using the drug.

Side effects

Criteria for evaluating the frequency of adverse reactions: very common (≥1/10), common (≥1/100, < 1/10), infrequent (≥1/1000, < 1/100), rare (≥1/10000, < 1/1000); very rare (< 1/10000); frequency unknown – cannot be estimated based on available data.

Overdose

Symptoms of moderate overdose

Nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.

Treatment

Rinse stomach, take activated charcoal. Treatment is symptomatic.

Serious overdose symptoms

Fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.

Treatment

Immediate hospitalization in specialized departments for emergency therapy – gastric lavage, determination of acid-base balance, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When performing alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when plasma concentration of salicylates is more than 500 mg/l (3.6 mmol/l) in adults and 300 mg/l (2.2 mmol/l) in children.

In case of overdose, seek medical attention immediately.

Pregnancy use

Similarities